Virtual Library
Start Your Search
Wei-Yuan Chang
Author of
-
+
P1.01 - Advanced NSCLC (ID 757)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Advanced NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 10/16/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P1.01-048 - Clinical Impact of EGFR Mutation on Brain Metastasis in NSCLC Patients: A Meta-Regression Analysis (ID 7312)
09:30 - 09:30 | Author(s): Wei-Yuan Chang
- Abstract
Background:
Though target agents like epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI) have shown activity in patients with brain metastasis, the impact of EGFR mutation on incidence of non-small cell lung cancer (NSCLC) with brain metastasis and treatment outcome remain inconclusive.
Method:
MEDLINE, PubMed, and EBSCO Libraries were systematically searched until August 31, 2015. Retrospective studies including investigating the correlation between EGFR mutation status with brain metastasis from NSCLC were included.
Result:
The result of the fourteen studies including 4432 patients indicated NSCLC patients with EGFR mutation have higher incidence of brain metastasis (Figure 1, odd ratio = 2.09, 95% CI: 1.72–2.53). And, EGFR mutations were associated with better survival in patients with brain metastasis from five studies though not statistically significant (Figure 2, hazard ratio = 0.47, 95% CI: 0.16–1.35). Figure 1. Meta-analysis of the association between EGFR mutation status and the risk of brain metastasis. Figure 1 Figure 2. Meta-analysis on mean overall survival among NSCLC patients with brain metastasis according to EGFR mutation status. Figure 2
Conclusion:
We found that EGFR mutation increased risk of brain metastasis but EGFR mutation might predict better survival with appropriate treatments.
-
+
P3.05 - Early Stage NSCLC (ID 721)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Early Stage NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 10/18/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P3.05-004 - The Impact of EGFR Mutations on Incidence and Survival of NSCLC Patients with Brain Metastasis: a Single Center Retrospective Study (ID 8322)
09:30 - 09:30 | Presenting Author(s): Wei-Yuan Chang
- Abstract
Background:
Lung cancer is the leading cause of cancer-related deaths worldwide. Despite advances in systemic therapy and improvements in survival for advanced non-small cell lung carcinoma (NSCLC), brain metastasis (BM) remained an important etiology of morbidity and mortality. This study was designed to analyze the association between the epidermal growth factor receptor (EGFR) mutation status and the incidence of brain metastases (BM) and associated survival.
Method:
We retrospectively investigated the medical records of 491 patients diagnosed with NSCLC stage I to stage III from 2004 to 2015, who were tested for EGFR mutations. The time from the diagnosis of advanced NSCLC to the development of BM and the overall median survival after BM development were evaluated and compared by EGFR mutation status.
Result:
Seventy-eight of 491 patients developed BM. From 280 patients had EGFR mutations, 49 patients developed BM and 29 of 211 patients harboring wild-type EGFR developed BM. Comparing with wild-type EGFR group, the incidence of subsequent BM was statistically higher in patients with EGFR mutations [49 (17.5%) vs. 29 (13.7%), p=0.023]. Patients with EGFR mutations also demonstrated the trend with longer overall survival (OS) after BM diagnosis than patients with wild-type EGFR (17.8 v.s. 12.2 months, HR:0.79 , 95% CI: 0.45-1.40, p = 0.416) (Figure 1). Figure 1
Conclusion:
Our data suggested that EGFR mutation is a predictive risk factor for the development of brain metastasis. Though there is no statistical significance, NSCLC patients with EGFR mutation and brain metastasis tend to have longer survival than those with EGFR wild type.
